Beam Therapeutics Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Beam Therapeutics Inc.
‘Epigenetic Engineering’ Gene Therapy From Epic Bio Shows Early Promise
The San Francisco-based company has taken a step forward with proof of concept for its ‘switch on or switch off’ approach to gene regulation via non-cutting CRISPR molecules.
Intellia Says Sickle Cell Therapy Still ‘Wide Open’ As Novartis And Others Exit
A long-anticipated pruning back of the ev vivo gene therapy pipeline for sickle cell disease has arrived with Novartis, Graphite Bio and Sangamo each dropping projects, but some challengers are looking ahead to a future of in vivo approaches to the condition.
Pfizer Ibrance India Case: ‘Willful Contempt’ Lands Local Firm In Soup
An Indian court has directed a local firm to pay a specified sum to Pfizer for contempt of court in a case pertaining to its patent on palbociclib, failing which its senior executive could face a two-week prison term.
Ibrance Generics Arrive In India, Patient Programs Add Free Drug Component
Pfizer’s Ibrance is set to lose exclusivity in the US only by 2027, but the Indian market is buzzing with activity as generics including from top-ranked drug maker Sun Pharma vie for a share of the pie. Competing CDK4/6 inhibitors are already available but can cut-price palbociclib versions alter market dynamics?
- Gene Therapy, Cell Therapy
- Large Molecule
- Other Names / Subsidiaries
- Guide Therapeutics, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.